What Does “Probably Benign” Mean on a Breast Ultrasound?

A “probably benign” result on a breast ultrasound means the radiologist identified a finding that has less than a 2% chance of being cancer. In the standardized scoring system used across breast imaging, this corresponds to a category called BI-RADS 3, and it sits in a specific gray zone between “definitely benign” and “suspicious.” The usual recommendation is short-interval follow-up imaging rather than immediate biopsy, which understandably leaves many people feeling uneasy about what comes next.

What the BI-RADS Scale Is and Where “Probably Benign” Fits

Breast imaging results are reported using a standardized system called BI-RADS (Breast Imaging Reporting and Data System), which assigns findings to numbered categories. Category 1 means the images look normal. Category 2 means there is a finding, but it is clearly benign. Category 4 means something looks suspicious enough to warrant a biopsy, and category 5 means malignancy is highly likely. Category 3 is the “probably benign” designation, defined as a finding with less than a 2% likelihood of being malignant.¹

Not every breast finding qualifies for category 3. On ultrasound, the classic probably benign findings include solid masses that are oval-shaped, have smooth borders, and lie parallel to the skin surface. Complicated cysts, which are fluid-filled sacs containing some debris, and clustered microcysts also historically fell into this category.² However, some of those findings have since accumulated enough evidence to be reclassified as definitively benign (category 2). Complicated cysts with debris, clustered microcysts, and multiple bilateral circumscribed masses now have sufficient data supporting a benign designation, which means they no longer need the follow-up protocol that category 3 requires.³

How Often “Probably Benign” Turns Out to Be Cancer

The formal threshold is under 2%, but real-world studies show a range depending on the population and how strictly radiologists apply the criteria. In a large study of over 1,100 patients with screening ultrasound findings followed for at least two years, the malignancy rate was about 0.7%.⁴ A prospective study using automated whole-breast ultrasound in women with dense breasts found no cancers at all in the same location as the BI-RADS 3 finding over two years of follow-up, and the overall cancer rates for BI-RADS 1, 2, and 3 findings were statistically indistinguishable.⁵

That said, not every study paints such a reassuring picture. A study tracking over 500 BI-RADS 3 lesions that grew during follow-up found a higher malignancy rate of about 5%. The key finding was that growth alone was not the main concern. What mattered most was whether the lesion changed shape or developed suspicious features on imaging. A mass that simply got a little bigger but kept its smooth, oval appearance had only about a 1.9% chance of being malignant.⁶ Another study that biopsied 122 BI-RADS 3 lesions found malignancy in about 5.7%, which the authors noted was higher than the expected under-2% benchmark.⁷

What explains the variation? A lot comes down to how carefully radiologists apply the criteria. When the probably benign label is reserved strictly for findings that meet the textbook description, the malignancy rate stays very low. When the label is used more loosely to categorize ambiguous findings that do not quite fit the classic pattern, the rate creeps up. The system works well when it is applied rigorously. It works less well when it becomes a parking spot for uncertainty.

What Happens After a “Probably Benign” Report

The standard recommendation for a BI-RADS 3 finding is short-interval follow-up, usually a repeat ultrasound at six months. If the finding looks stable at six months, another check happens at twelve months, then again at about twenty-four months. If the lesion remains unchanged over two years, it is typically downgraded to benign (category 2) and you return to routine screening. In one large study, imaging follow-up of 252 BI-RADS 3 masses confirmed stability over this timeline, and among 80 that were biopsied, only three turned out to be malignant. All three were caught within six months, were smaller than a centimeter, and had not spread to lymph nodes.⁸

The follow-up approach is not just about watching and hoping. It is a strategy built on evidence showing that cancers missed by the initial assessment tend to reveal themselves early through changes in shape, margin, or size, while benign findings stay put. The two-year window is long enough to catch slow-growing cancers that might otherwise hide.

Still, not everyone completes the full follow-up. In a study of over 2,300 BI-RADS 3 lesions, about 7.5% underwent biopsy instead. Most of those biopsies happened upfront rather than after a follow-up visit, and the most common reason was simply patient or physician preference rather than a change in the imaging appearance.⁹ Wanting an answer now is a perfectly valid reason for pursuing a biopsy. Nobody should feel pressured into waiting if the uncertainty is causing significant distress.

When Biopsy Gets Recommended Instead of Follow-Up

There are situations where a radiologist or your doctor may recommend biopsy even for a BI-RADS 3 finding. If you can feel the lump, if you are about to start treatments that make follow-up impractical (like chemotherapy for another condition), or if you have severe anxiety about the result, biopsy becomes a reasonable first step. The same study of over 2,300 lesions found that palpable and larger masses in women under 40 were more likely to be biopsied right away.⁹

Pregnancy and breastfeeding present a particular challenge. Breast tissue changes dramatically during these periods, and many benign lesions can grow, develop unusual internal patterns, or look more suspicious than they would otherwise. At the same time, pregnancy-associated breast cancers do not always look obviously malignant on imaging. For this reason, guidelines suggest biopsy for BI-RADS 3 findings during pregnancy or lactation when clinical or radiological doubt persists, even though a BI-RADS 3 finding in a non-pregnant patient would normally just get a follow-up scan.¹⁰

Palpable masses specifically assessed as BI-RADS 3 have been studied separately. In a retrospective review of 197 palpable BI-RADS 3 masses and 376 palpable BI-RADS 4A masses, none of the cancers occurred in the BI-RADS 3 group. All nine cancers were in the 4A group. The researchers concluded that palpable BI-RADS 3 masses, particularly in younger women, can safely undergo surveillance rather than immediate biopsy.¹¹

Does Your Age Affect the Risk?

Age matters, though not in a straightforward way. A study examining the positive predictive value of each BI-RADS category across age groups found that the malignancy rate for category 3 varied significantly. In the youngest group the rate was about 0.9%, while a middle-aged group had a higher rate of about 3.9%, and the oldest group fell to about 2%.¹² The fact that the relationship is not a simple upward trend with age suggests that multiple factors are at play, including the types of lesions that tend to occur at different ages and how the criteria perform across different breast tissue compositions.

A separate study of palpable masses found that all malignancies in combined BI-RADS 3 and 4A groups occurred in women over 40, with a significant increase in cancer rate across age quartiles.¹¹ This makes practical sense: breast cancer becomes more common with age, so a finding that looks the same on imaging carries slightly more statistical risk in an older person than a younger one. Your doctor takes your age and personal risk factors into account when deciding whether follow-up or biopsy makes more sense.

The Anxiety Problem

The phrase “probably benign” is genuinely confusing. It sounds reassuring if you emphasize “benign” and alarming if you emphasize “probably.” Research confirms that this label causes significant anxiety in patients and also creates confusion among referring physicians who may not be deeply familiar with the BI-RADS system.¹³ The anxiety is real enough that at least one study investigated using a specialized excision system to remove BI-RADS 3 lesions in women with severe breast cancer anxiety, treating the psychological burden as a legitimate clinical problem worth addressing.¹⁴

Part of the problem is communication. A study of women receiving abnormal mammogram results found that about 30% reported less than full understanding of what their doctor explained. Among women with a suspicious abnormality, only about half understood their result to be abnormal. Women who consulted with their primary care doctor were roughly twice as likely to report full understanding. If you get a “probably benign” result and are not sure what it means for you specifically, asking your primary care doctor to walk through it can make a real difference.

The screening context also matters. If you had a routine screening ultrasound with no symptoms and no suspicious mammogram findings, the malignancy rate for your BI-RADS 3 finding drops further. In the study mentioned earlier, the malignancy rate was about 0.4% for patients whose mammograms were normal, compared to about 2.2% when the mammogram was also abnormal.⁴ Knowing your specific context can help calibrate how much worry is justified.

Why Two Radiologists Might Read the Same Image Differently

One uncomfortable reality is that radiologists do not always agree on which category a finding belongs in. Studies measuring agreement between observers on BI-RADS ultrasound classifications have found only fair overall agreement, with one study reporting a kappa value of 0.30, which in plain terms means radiologists agreed on the category only modestly better than chance.¹⁵ Agreement tends to be better at the extremes. Radiologists generally agree on findings that are clearly benign (category 2) or clearly malignant (category 5). The disagreement concentrates in the middle categories, particularly categories 3 and 4, where the boundary is inherently fuzzy.¹⁶

This does not mean the system is broken. It means ultrasound interpretation involves judgment, and reasonable experts sometimes make different judgment calls on borderline findings. When assessing specific features of a lesion, radiologists show stronger agreement on some characteristics (such as whether calcifications are present) and weaker agreement on others (such as the margin and internal echo pattern of a mass).¹⁷ If you feel uncertain about a borderline result, seeking a second opinion from a breast imaging specialist is a reasonable step.

When Ultrasound and Mammography Give Different Answers

Sometimes the ultrasound says “probably benign” but the mammogram says something different, or vice versa. This kind of discordance is not rare, and it creates a genuine clinical dilemma. A retrospective study of 706 women with discordant ultrasound and mammography results found that using a statistical tool alongside the imaging reduced unnecessary biopsies substantially while also cutting the rate of missed cancers. When paired with the ultrasound, the rate of unnecessary biopsies dropped from about 74% to about 44%, and missed malignancies fell from about 13% to about 2%.¹⁸

The practical takeaway is that when one imaging method calls a finding benign or probably benign while another flags it as suspicious, the suspicious reading usually wins, and further evaluation is recommended. If your ultrasound is BI-RADS 3 but your mammogram is BI-RADS 4, your doctor will likely recommend a biopsy rather than watch-and-wait.

The Cost Question

The follow-up approach is not just evidence-based but also cost-effective. A cost comparison found that two years of imaging follow-up for a probably benign ultrasound finding cost about $615, compared to roughly $1,173 for the least expensive ultrasound-guided biopsy scenario. Follow-up remained cheaper in every comparison except one specific situation involving MRI-guided biopsy in average-risk patients without a post-biopsy follow-up MRI.¹⁹ The cost difference is worth knowing about, particularly if you are weighing the financial implications of choosing surveillance versus requesting a biopsy for peace of mind.

AI Tools on the Horizon

One of the most active areas of research in breast imaging involves using artificial intelligence to help radiologists classify borderline findings more accurately. Computer-aided diagnostic tools applied to automated breast ultrasound images have shown promise in characterizing BI-RADS 3 and 4 lesions, with the potential to reduce unnecessary biopsies.²⁰ A multi-center study testing a transformer-based AI model found that after radiologists consulted the AI’s classification, their accuracy, sensitivity, and consistency all improved significantly, with inter-observer agreement rising in almost all radiologists tested.²¹ Given the observer variability problem, tools that help push radiologists toward more consistent calls could meaningfully reduce both unnecessary biopsies and missed cancers.

“Probably Benign” Findings in Men

Most conversations about breast ultrasound focus on women, but men get breast imaging too, usually when they notice a lump or breast enlargement. In a study of 560 male breast lesions evaluated by ultrasound, about 34% were classified as BI-RADS 3.²² Most male breast findings turn out to be gynecomastia, which is benign tissue growth driven by hormonal factors. A separate study of 557 male patients found that imaging had high accuracy overall, with a negative predictive value over 99%, and malignancies were diagnosed in under 1% of patients.²³ The probably benign category applies in male breast imaging just as it does in female breast imaging, though the underlying conditions tend to be different and the overall cancer risk is much lower.